Shares of Myriad Genetics were higher after it announced early access to the FirstGene Multiple Prenatal Screen. The stock was up 9.2% to $4.87 Tuesday and is down about 64% this year.

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...

Epigenetic changes do not alter the genetic code itself, but by changing how DNA is organized within the cell, epigenetic ...

Early access via large-scale clinical study to establish the validity and utility of the FirstGene TM screen ...

Jeff Jackson, alfalfa and forage specialist with WinField United, showed and explained the new and solid-line forages, such ...

Opus Genetics shares were up 22% at $1.21, after the company said it saw positive topline results from a pivotal Phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

Adopting a healthy lifestyle that includes plenty of physical activity and a low fat diet is a necessary step when waging the ...

Discover how cystic fibrosis genetics affect inheritance patterns and symptom. Learn about CFTR mutations, testing options, ...

Several genetic markers contribute to our final eye color shade. A baby born with blue eyes can have brown eyes by their 1st ...